Clinical Study
Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
Table 2
Incidence of toxicities in treated patients.
| | Toxicities | Normal no. (%) | G1,2 no. (%) | G3 no. (%) | G4 no. (%) |
| | Haematological toxicity | | | | | | Neutropenia | 34 (58.6) | 16 (27.6) | 8 (13.8) | — | | Febrile neutropenia | 40 (69) | 15 (25.9) | 2 (3.4) | 1 (1.7) | | Anemia | 20 (34.5) | 34 (58.6) | 4 (6.9) | — | | Thrombocytopenia | 50 (86.2) | 8 (13.8) | — | — | | Nonhaematological toxicity | | | | | | Skin and nail disorders | 4 (6.9) | 26 (44.8) | 11 (19) | 17 (29.3) | | Scaling | 16 (27.6) | 25 (43.1) | 9 (15.5) | 8 (13.8) | | Stomatitis | 30 (51.7) | 20 (34.5) | 6 (10.3) | 2 (3.4) | | Hand-foot syndrom | 23 (39.7) | 15 (25.9) | 6 (10.3) | 14 (24.1) | | Erythema | 48 (82.8) | 10 (17.2) | — | — | | Paresis | 27 (46.6) | 17 (29.3) | 10 (17.2) | 4 (6.9) | | Paresthesia | 20 (34.4) | 16 (27.6) | 19 (32.8) | 3 (5.2) | | Myalgia | 41 (70.7) | 11 (19) | 4 (6.9) | 2 (3.4) | | Arthralgia | 23 (39.7) | 19 (32.8) | 13 (22.4) | 3 (5.1) | | Nausea | 6 (10.3) | 36 (62.1) | 10 (17.2) | 6 (10.3) | | Vomiting | 21 (36.2) | 25 (43.1) | 7 (12.1) | 5 (8.6) | | Fluid retention | 38 (65.5) | 18 (31.1) | 2 (3.4) | — | | Phlebitis | 51 (87.9) | 4 (6.9) | 3 (5.2) | — | | Any grade 4 event | | 32 (55%) | | | Death | | 2 (3.4) | |
|
|
